A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation (original) (raw)

• Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. & Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329–341 (2010).
  Article CAS Google Scholar
• Hawkins, P.T., Anderson, K.E., Davidson, K. & Stephens, L.R. Signalling through Class I PI3Ks in mammalian cells. Biochem. Soc. Trans. 34, 647–662 (2006).
  Article CAS Google Scholar
• Bohnacker, T. et al. PI3Kγ adaptor subunits define coupling to degranulation and cell motility by distinct PtdIns(3,4,5)P3 pools in mast cells. Sci. Signal. 2, ra27 (2009).
  Article Google Scholar
• Ghigo, A., Damilano, F., Braccini, L. & Hirsch, E. PI3K inhibition in inflammation: toward tailored therapies for specific diseases. Bioessays 32, 185–196 (2010).
  Article CAS Google Scholar
• Foukas, L.C. et al. Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441, 366–370 (2006).
  Article CAS Google Scholar
• Ji, H. et al. Inactivation of PI3Kγ and PI3Kδ distorts T-cell development and causes multiple organ inflammation. Blood 110, 2940–2947 (2007).
  Article CAS Google Scholar
• Ciraolo, E. et al. Phosphoinositide 3-kinase p110β activity: key role in metabolism and mammary gland cancer but not development. Sci. Signal. 1, ra3 (2008).
  Article Google Scholar
• Maira, S.M. et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851–1863 (2008).
  Article CAS Google Scholar
• Brachmann, S.M. et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. USA 106, 22299–22304 (2009).
  Article CAS Google Scholar
• Konstantinidou, G. et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 69, 7644–7652 (2009).
  Article CAS Google Scholar
• Toledo, L.I. et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat. Struct. Mol. Biol. 18, 721–727 (2011).
  Article CAS Google Scholar
• Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035–1044 (2007).
  Article CAS Google Scholar
• Bantscheff, M. et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 29, 255–265 (2011).
  Article CAS Google Scholar
• Kruse, U. et al. Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells. Leukemia 25, 89–100 (2011).
  Article CAS Google Scholar
• Knight, Z.A. et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125, 733–747 (2006).
  Article CAS Google Scholar
• Vlahos, C.J., Matter, W.F., Hui, K.Y. & Brown, R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H–1-benzopyran-4-one (LY294002). J. Biol. Chem. 269, 5241–5248 (1994).
  CAS Google Scholar
• Cansfield, A., Bergamini, G. & Neubauer, G. Selectivity profiling of PI3K interacting molecules against multiple targets. European patent EP2245181 (2011).
• Jefferies, H.B. et al. A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding. EMBO Rep. 9, 164–170 (2008).
  Article CAS Google Scholar
• Sharma, K. et al. Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat. Methods 6, 741–744 (2009).
  Article CAS Google Scholar
• Berg, E.L. et al. Chemical target and pathway toxicity mechanisms defined in primary human cell systems. J. Pharmacol. Toxicol. Methods 61, 3–15 (2010).
  Article CAS Google Scholar
• Hirsch, E. et al. Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation. Science 287, 1049–1053 (2000).
  Article CAS Google Scholar
• Jones, G.E. et al. Requirement for PI 3-kinase γ in macrophage migration to MCP-1 and CSF-1. Exp. Cell Res. 290, 120–131 (2003).
  Article CAS Google Scholar
• Savitski, M.M. et al. Targeted data acquisition for improved reproducibility and robustness of proteomic mass spectrometry assays. J. Am. Soc. Mass Spectrom. 21, 1668–1679 (2010).
  Article CAS Google Scholar
• Williams, O. et al. Discovery of dual inhibitors of the immune cell PI3Ks p110δ and p110γ: a prototype for new anti-inflammatory drugs. Chem. Biol. 17, 123–134 (2010).
  Article CAS Google Scholar
• Mitsdoerffer, M. et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc. Natl. Acad. Sci. USA 107, 14292–14297 (2010).
  Article CAS Google Scholar
• Zhou, L. et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8, 967–974 (2007).
  Article CAS Google Scholar
• Patrucco, E. et al. PI3Kγ modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118, 375–387 (2004).
  Article CAS Google Scholar
• Rommel, C., Camps, M. & Ji, H. PI3K δ and PI3K γ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol. 7, 191–201 (2007).
  Article CAS Google Scholar
• Rückle, T., Schwarz, M.K. & Rommel, C. PI3Kγ inhibition: towards an 'aspirin of the 21st century'? Nat. Rev. Drug Discov. 5, 903–918 (2006).
  Article Google Scholar
• Martin, D. et al. PI3Kγ mediates Kaposi's sarcoma–associated herpesvirus vGPCR-induced sarcomagenesis. Cancer Cell 19, 805–813 (2011).
  Article CAS Google Scholar
• Schmid, M.C. et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3Kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19, 715–727 (2011).
  Article CAS Google Scholar
• Becattini, B. et al. PI3Kγ within a nonhematopoietic cell type negatively regulates diet-induced thermogenesis and promotes obesity and insulin resistance. Proc. Natl. Acad. Sci. USA 108, E854–E863 (2011).
  Article CAS Google Scholar
• Kobayashi, N. et al. Blockade of class IB phosphoinositide-3 kinase ameliorates obesity-induced inflammation and insulin resistance. Proc. Natl. Acad. Sci. USA 108, 5753–5758 (2011).
  Article CAS Google Scholar
• Fougerat, A. et al. Genetic and pharmacological targeting of phosphoinositide 3-kinase-γ reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation 117, 1310–1317 (2008).
  Article CAS Google Scholar
• Fadden, P. et al. Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chem. Biol. 17, 686–694 (2010).
  Article CAS Google Scholar
• Graves, P.R. et al. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol. Pharmacol. 62, 1364–1372 (2002).
  Article CAS Google Scholar
• Camps, M. et al. Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11, 936–943 (2005).
  Article CAS Google Scholar
• Bilancio, A. et al. Key role of the p110δ isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110δ function in B cells. Blood 107, 642–650 (2006).
  Article CAS Google Scholar
• Condliffe, A.M. et al. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106, 1432–1440 (2005).
  Article CAS Google Scholar
• Vecchione, C. et al. Protection from angiotensin II–mediated vasculotoxic and hypertensive response in mice lacking PI3Kγ. J. Exp. Med. 201, 1217–1228 (2005).
  Article CAS Google Scholar
• Haylock-Jacobs, S. et al. PI3Kδ drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting TH17 differentiation. J. Autoimmun. 36, 278–287 (2011).
  Article CAS Google Scholar
• Konrad, S. et al. Phosphoinositide 3-kinases γ and δ, linkers of coordinate C5a receptor-Fcγ receptor activation and immune complex-induced inflammation. J. Biol. Chem. 283, 33296–33303 (2008).
  Article CAS Google Scholar
• Lubberts, E. et al. Treatment with a neutralizing anti–murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50, 650–659 (2004).
  Article CAS Google Scholar
• Genovese, M.C. et al. LY2439821, a humanized anti–interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 62, 929–939 (2010).
  Article CAS Google Scholar
• Kageyama, Y., Kobayashi, H. & Kato, N. Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis. Mod. Rheumatol. 19, 657–662 (2009).
  Article CAS Google Scholar
• Savitski, M.M. et al. Delayed fragmentation and optimized isolation width settings for improvement of protein identification and accuracy of isobaric mass tag quantification on Orbitrap-type mass spectrometers. Anal. Chem. 83, 8959–8967 (2011).
  Article CAS Google Scholar
• Savitski, M.M., Scholten, A., Sweetman, G., Mathieson, T. & Bantscheff, M. Evaluation of data analysis strategies for improved mass spectrometry-based phosphoproteomics. Anal. Chem. 82, 9843–9849 (2010).
  Article CAS Google Scholar
• Kunkel, E.J. et al. An integrative biology approach for analysis of drug action in models of human vascular inflammation. FASEB J. 18, 1279–1281 (2004).
  Article CAS Google Scholar
• Kunkel, E.J. et al. Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models. Assay Drug Dev. Technol. 2, 431–441 (2004).
  Article CAS Google Scholar